James R. Kasinger
2017
In 2017, James R. Kasinger earned a total compensation of $1.4M as General Counsel at CRISPR Therapeutics AG.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Non-Equity Incentive Plan | $98,499 |
| Option Awards | $1,086,260 |
| Salary | $205,513 |
| Total | $1,420,272 |
Kasinger received $1.1M in option awards, accounting for 76% of the total pay in 2017.
Kasinger also received $30K in bonus, $98.5K in non-equity incentive plan and $205.5K in salary.
Rankings
In 2017, James R. Kasinger's compensation ranked 7,263rd out of 14,666 executives tracked by ExecPay. In other words, Kasinger earned more than 50.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,263 out of 14,666 | 51st |
Division Manufacturing | 2,702 out of 5,768 | 53rd |
Major group Chemicals And Allied Products | 881 out of 2,074 | 58th |
Industry group Drugs | 689 out of 1,730 | 60th |
Industry Biological Products, Except Diagnostic Substances | 128 out of 316 | 60th |
Source: SEC filing on April 30, 2019.
Kasinger's colleagues
We found four more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2017.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019